Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and Adoptive T-cell Therapy in Metastatic Merkel Cell Carcinoma
NCT02584829Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 2015
- Primary completion
- Dec 2018
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
A Phase 2 trial of MCPyV TAg-specific polyclonal autologous CD8-positive T cells in Merkel cell carcinoma (MCC), sponsored by Fred Hutchinson Cancer Center. Started Nov 2015; status: terminated.
02
Drugs
MCPyV TAg-specific polyclonal autologous CD8-positive T cells
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT02584829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02584829.